Johnston et al. [32] showed that, in the PALLET trial involving ER-positive and HER2-negative breast cancer patients, the concomitant use of a CDK4/6 inhibitor and endocrine therapy significantly decreased Ki67 LI compared with endocrine therapy alone. Here, ERBB2 is linked to breast cancer.